Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID‐19 Booster Vaccination—A Population‐Based Study of 3066 Individuals
Daniela Sieghart, Galateja Jordakieva, Caroline Dürrschmid, Claudia A Hana, Lan Vi Tran, Leonhard X Heinz, Helmuth Haslacher, Markus Zlesak, Valentin Marzoner, Philip Nasztl, Giulia Piccini, Alessandro Manenti, Emanuele Montomoli, Anselm Jorda, Clemens Fedrizzi, Timothy Hasenoehrl, Andrej Zdravkovic, Karolina Anderle, Ursula Wiedermann, Susanne Drapalik, Helmut Steinbrecher, Felix Bergmann, Christa Firbas, Barbara Wagner, Margherita Leonardi, Giulio Pierleoni, Matilde Ballini, Linda Benincasa, Serena Marchi, Claudia Maria Trombetta, Thomas Perkmann, Richard Crevenna, Markus Zeitlinger, Michael Bonelli, Daniel Aletaha, Helga Radner · 2026
Read Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID‐19 Booster Vaccination—A Population‐Based Study of 3066 Individuals by Daniela Sieghart, Galateja Jordakieva, Caroline Dürrschmid, Claudia A Hana, Lan Vi Tran, Leonhard X Heinz, Helmuth Haslacher, Markus Zlesak, Valentin Marzoner, Philip Nasztl, Giulia Piccini, Alessandro Manenti, Emanuele Montomoli, Anselm Jorda, Clemens Fedrizzi, Timothy Hasenoehrl, Andrej Zdravkovic, Karolina Anderle, Ursula Wiedermann, Susanne Drapalik, Helmut Steinbrecher, Felix Bergmann, Christa Firbas, Barbara Wagner, Margherita Leonardi, Giulio Pierleoni, Matilde Ballini, Linda Benincasa, Serena Marchi, Claudia Maria Trombetta, Thomas Perkmann, Richard Crevenna, Markus Zeitlinger, Michael Bonelli, Daniel Aletaha, Helga Radner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13418372.txt.
Description
Daniela Sieghart and co-authors examine whether ABO blood group affects antibody responses and breakthrough infections after a COVID-19 booster vaccine. Their 2026 population-based study follows 3,066 adults across several centres, with antibody measurements at baseline, four weeks, and six months.
Blood group showed no association with antibody levels against the virus's receptor binding domain, or with neutralising antibodies against the original virus or the Omicron variant, four weeks after boosting. Rhesus type also showed no effect. Breakthrough infections, however, were least common in blood group AB and showed a similar trend in group B, compared with group O. Neither blood system related to how severe breakthrough illness became. The authors suggest ABO differences may matter for Omicron transmission even without changing antibody responses.
Catalog record
| CREATOR | Daniela Sieghart, Galateja Jordakieva, Caroline Dürrschmid, Claudia A Hana, Lan Vi Tran, Leonhard X Heinz, Helmuth Haslacher, Markus Zlesak, Valentin Marzoner, Philip Nasztl, Giulia Piccini, Alessandro Manenti, Emanuele Montomoli, Anselm Jorda, Clemens Fedrizzi, Timothy Hasenoehrl, Andrej Zdravkovic, Karolina Anderle, Ursula Wiedermann, Susanne Drapalik, Helmut Steinbrecher, Felix Bergmann, Christa Firbas, Barbara Wagner, Margherita Leonardi, Giulio Pierleoni, Matilde Ballini, Linda Benincasa, Serena Marchi, Claudia Maria Trombetta, Thomas Perkmann, Richard Crevenna, Markus Zeitlinger, Michael Bonelli, Daniel Aletaha, Helga Radner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |